US FDA Deems Synapse’s Clinical Trials ‘Unacceptable’

 
• By Urtė Fultinavičiūtė
  
One line illustration of hangs gestures indicating dispute or disapproval
The FDA downgraded several products to a BX rating after raising data integrity concerns at a CRO. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics